The projects of the Clinical and Experimental Neurooncology Laboratory focus on the biology of tumors of the nervous system, with special emphasis on molecular mechanisms of tumorigenesis, acquired therapy resistance, and treatment-induced vulnerability. Our projects are translationally oriented, i.e. the questions of our projects are based on unsolved clinical challenges. Our ambition is to achieve further development of therapeutic strategies in phase I/II trials. Our research projects thus span the entire translational chain of discovery, validation and application with constant forward and reverse translation.
We would like to welcome you to our newsfeed.
January 2025
Another publication entitled “The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy” was published in Neuron-Oncology Advances (IF:3.7).
We are more than happy to share with you the first publication of 2025. “Genome-wide CRISPR-Cas 9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma” was published in Neuro-Oncology (IF.:16.4)
December 2024
Just published in Genome Biology (IF.:10.1)“Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors”
October 2024
EANO 2024 in Glasgow
Looking forward to an exciting Annual EANO meeting in Glasgow!
September 2024
ESMO 2024 Annual Meeting in Barcelona:
Excited to present first results of the Dose Escalation Part of the first-in-man phase 1 trial investigating CureVac`s mRNA vaccine candidate CVGBM
August 2024
In the newly launched podcast‘Key To My Research’, our Department Chair Professor Tabatabai talks about the topic ‘How intelligent are tumours?’
We bid farewell to our medical doctoral student Louise Maise on her Erasmus-funded semester abroad in Rome.
Hot-off the press. In the journal ‘Acta Neuropathologica Communications’ (IF.: 6.2) you will find the paper entitled‘Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma’by our PhD student Foteini Tsiami on the role of DNMT1 in sonic hedgehog-altered medulloblastomas.
Congratulations to all involved especially Foteini and Daniel Merk.
July 2024
As part of the ‘Tübingen Therapy Symposium Neurooncology 2024’ on 31 July 2024, speakers from our specialist departments provided insights into recent cases, current findings, new clinical studies and therapeutic options.
The highlight of our exciting interdisciplinary programme were four contributions from our patients on the topics of glioblastoma, IDH-mutated glioma, meningeosis neoplastica and vestibular schwannoma.
They reported on their perspectives, attitudes and suggestions.
We would like to thank all contributors and speakers and the approximately 100 participants in the audience for this very enjoyable event.
The smooth running of the event would not have been possible without the support in front of and behind the scenes. We would like to sincerely thank Ms Gramer, Dr Dickreuter, Ms Pelz, Dr Rieger, Dr Becker, Mr Lang and Mr Wehle.
Finally out! ‘CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines’led by Dr Daniel Merk and our head Ghazaleh Tabatabai can be found in the journal Genome Medicine (IF.:10.4). Congratulations to all involved and happy reading!
AnnualDIAMOND meeting in Berlin. We look back on a lot of interaction between mentors and new contacts.
Our medical doctoral student Jil Trampert returns to the lab from her semester abroad in Marseille, reinvigorated and with lots of new ideas. We look forward to get back to work together!
June 2024
ASCO 2024 ‘Connect, collaborate and grow’ We are looking forward to all the interactions, meetings and discussions at this year's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Many exciting contributions from the field of neuro-oncology.
On 19 June 2024, a ‘Post-ASCO’ meeting will take place in Tübingen with the relevant key messages.
May 2024
We congratulate our head of department, Ghazaleh Tabatabai on her election as spokesperson of the DFG Board for Neuroscience.
Another great seminar by Mrs Andrea Och on the topic of ‘Networking Strategies’.
April 2024
We are very happy about the successful defence of our former PhD student Bianca Walter, now finally Dr. rer. nat. Walter!
More information about her thesis with the name: ‘Understanding, inducing and exploiting actionable vulnerabilities in experimental glioma’
We are delighted about the seminar held by Prof. Thomas Schuhmacher as part of the DIAMOND programme on the topic of ‘Leadership and organisation in science and hospitals: managing complexity and effectiveness’. Many thanks for the organisation on site by Dr rer. nat. Sarah Erdmann.
March 2024
On World Women's Day, Prof Tabatabai and Prof Lisa Sevenich give exciting insights into their individual career paths.
We are overjoyed to publish our paper‘Functionally-instructed modifiers of response to ATR inhibition in experimental glioma’ in the ‘Journal of Experimental & Clinical Cancer Research’ (IP:11.3) with our first author Bianca Walter.
Further information, including a thread, can be found on LinkedIn and X.
We are excited about the start of the new DIAMOND cohort. Our colleagues, Jil Trampert, Surender Surender and Foteini Tsiami are looking forward to exciting seminars and the upcoming dates.
February 2024
We wish our medical doctoral student Jil Trampert a lot of fun in her Erasmus-funded semester abroad in Marseille.
January 2024
The newly published study on ‘Patient-reported outcomes’ using the TRACE app under the direction of Prof Renovanz can be found in the journal ‘Neuro-Oncology Practice’ - Many thanks to all co-authors.
December 2023
We warmly welcome University Professor Lisa Sevenich as newly appointed W2 Professor for ‘Experimental Neuro-Onco-Immunology’ in our department.
October 2023
We are pleased to welcome Ms Melissa Lang-Schnee for her lab rotation and bachelor thesis in our lab.
September 2023
At the annual meeting of the European Society of Neurooncology (EANO) in Rotterdam, we were able to gather valuable discussion about our projects in the poster session and the lecture session.
We are particularly pleased about the poster prize for Prof Mirjam Renovanz in the ‘Supportive care’ category on the results of the TRACE app, as well as the ‘selected abstract talk’ by Ms Foteini Tsiami on epigenetic regulators as a drug target in experimental sonic hedgehog medulloblastomas.
We are pleased about the great presentation of our medical doctoral students Ms Jil Trampert and Mr Felix Krautwurst at the IZKF mid-term colloquium.
We welcome Dr rer. nat. Sarah Erdmann, who will support us as a postdoctoral researcher from now on, especially in the ‘in vivo’ area as well as in science and laboratory management.
We look forward to working with her and wish her a pleasant start.
April 2023
We warmly welcome our new medical doctoral students Jil Trampert and Felix Krautwurst, who will be supporting us in the coming period. We wish them a pleasant and instructive start.
We are pleased to present a detailed and explanatory video regarding our publication ‘Clinical outcome of biomarker-guided therapies in adult patients with tumours of the nervous system.’
March 2023
We had an eventful and instructive time at the iFit Conference in Zell am See.
Bianca Walter and Dr Daniel Merk were able to present and discuss their current results.
We are pleased about the publication: ‘Clinical outcome of biomarker-guided therapies in adult patients with tumours of the nervous system.’ which was published in March in the journal Neurooncology Advances.
We warmly welcome our new colleague:Surender Surender will join us as a PhD student. We wish him an instructive and pleasant start.
January 2023
We welcome our new employees:
Mrs. Anke Jacob will support us from now on as a medical technical assistant, mainly in cell culture work.Ms. Bsc. Viktoria Dimanova will complete a laboratory rotation with us as part of her Master's degree in "Molecular Medicine".We wish both of them a pleasant start and look forward to working together.
December 2022
We wish you a Merry Christmas and a Happy New Year!We had a great Christmas party at the Hertie Institute and are happy about the distributed Christmas presents.
November 2022
Parts of our preclinical and clinical team will attend the annual meeting of the Society of Neurooncology (SNO) (16.11-20.11.2022).
+49 (0)7071-
29-83266
+49 (0)7071-
29-80449
+49 (0)7071-
29-83618
+49 (0)7071-
29-81987
+49 (0)7071-
29-83269
+49 (0)7071-
29-82174
+49 (0)7071-
29-81987
+49 (0) 7071-
29-82174
+49 (0)7071-
29-81987
+49 (0)7071-
29-83266
+49 (0)7071-
29-81987
+49 (0)7071
29-81960
+49 (0)7071-
29-85018
+49 (0)7071-
29-82001
+49 (0)7071-
29-82043
Link Google Scholar
Selected Publications (last 3 years)
Merk DJ, Tsiami F, Hirsch S, Walter B, Haeusser LA, Maile JD, Stahl A, Jarboui MA, Lechado-Terradas A, Klose F, Babaei S, Admard J, Casadei N, Roggia C, Spohn M, Schittenhelm J, Singer S, Schüller U, Piccioni F, Persky NS, Claassen M, Tatagiba M, Kahle PJ, Root DE, Templin M, Tabatabai G. Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. Genome Biol. 2024 Dec 2;25(1):301. doi: 10.1186/s13059-024-03438-w. PMID: 39617889; PMCID: PMC11610224.
Tabatabai G,Platten M, Preusser M, Weller M, Wick W, van den Bent M. Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored? Neuro Oncol. 2024 Nov 19:noae225. doi: 10.1093/neuonc/noae225. Epub ahead of print. PMID: 39561243.
Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, […], Tabatabai G, Tabouret E, Short S, Wen PY, Weller M, Le Rhun E, Wesseling P, van den Bent M, Preusser M. EANO guideline on molecular testing of meningiomas for targeted therapy selection. Neuro Oncol. 2024 Nov 22:noae253. doi: 10.1093/neuonc/noae253. Epub ahead of print. PMID: 39577862.
Singer S, Schranz M, Hippler M, Kuchen R, Weiß Lucas C, Meixensberger J, Fehrenbach MK, Keric N, Mitsdoerffer M, Gempt J, Coburger J, Kessler AF, Wehinger J, Misch M, Onken J, Rapp M, Voß M, Nadji-Ohl M, Mehlitz M, Tatagiba M, Tabatabai G, Renovanz M. Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study. Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653. Epub ahead of print. PMID: 39550627.
Landry AP, Wang JZ, Patil V, […],Tabatabai G, Tatagiba M, Behling F, Barnholtz-Sloan JS, Sloan AE, Chotai S, Chambless LB, Mansouri A, Ehret F, Capper D, Tsang DS, Aldape K, Gao A; International Consortium on Meningiomas (ICOM); Nassiri F, Zadeh G. Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: a multicenter prospective study. Neuro Oncol. 2024 Nov 6:noae236. doi: 10.1093/neuonc/noae236. Epub ahead of print. PMID: 39503370.
Zeyen T, Böhm L, Paech D, […] Tabatabai G, […], Herrlinger U, Weller J, Schaub C. Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ. Neuro Oncol. 2024 Oct 1:noae205. doi: 10.1093/neuonc/noae205. Epub ahead of print. PMID: 39351820.
Wang JZ, Patil V, Landry, […] Tabatabai G, Tatagiba M, Behling, […], Aldape K, Nassiri F, Zadeh G. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma. Nat Med. 2024 Nov;30(11):3173-3183. doi: 10.1038/s41591-024-03167-4. Epub 2024 Aug 21. PMID: 39169220; PMCID: PMC11564112.
Beer SA, Möhle R, Tabatabai G, Merle DA, Ernemann U, Richter V, Lengerke C. Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382-4. Epub ahead of print. PMID: 39122834.
Tsiami F, Lago C, Pozza N, Piccioni F, Zhao X, Lülsberg F, Root DE, Tiberi L, Kool M, Schittenhelm J, Bandopadhayay P, Segal RA, Tabatabai G, Merk DJ. Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma. Acta Neuropathol Commun. 2024 Aug 7;12(1):125. doi: 10.1186/s40478-024-01831-x. PMID: 39107797; PMCID: PMC11304869.
Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, Walter B, Brown A, Persky NS, Root DE, Tabatabai G.CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines. Genome Med. 2024 Jun 17;16(1):82. doi: 10.1186/s13073-024-01341-4. PMID: 38886809; PMCID: PMC11181638.
Maier SH, Schönecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, Büttner M, Kaul D, Imhoff D, Fokas E, Seidel C, Hau P, Kölbl O, Popp I, Grosu AL, Haussmann J, Budach W, Celik E, Kahl KH, Hoffmann E, Tabatabai G, Paulsen F, Holzgreve A, Albert NL, Mansmann U, Corradini S, Belka C, Niyazi M, Bodensohn R. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol. 2024 May 4;47:100790. doi: 10.1016/j.ctro.2024.100790. PMID: 38765202; PMCID: PMC11101689.
Feucht D, Haas P, Skardelly M, Behling F, Rieger D, Bombach P, Paulsen F, Hoffmann E, Hauser TK, Bender B, Renovanz M, Niyazi M, Tabatabai G, Tatagiba M, Roder C. Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival. Neurooncol Adv. 2024 Apr 3;6(1):vdae053. doi: 10.1093/noajnl/vdae053. PMID: 38680987; PMCID: PMC11046984.
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, Frevert ML, Matovina S, Englisch A, Tegeler CM, Rohner A, Seller A, Hahn M, Pfister K, Fink A, Popp I, Lorenz S,Tabatabai G, Juhasz-Böss I, Janni W, Brucker S, Taran FA, Hartkopf A, Schäffler H. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. ESMO Open. 2024 Apr 17;9(5):102995. doi: 10.1016/j.esmoop.2024.102995. Epub ahead of print. PMID: 38636292.
Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S, Haeusser LA, Tsiami F, Plöger S, Aghaallaei N, Dick AM, Skokowa J, Schmees C, Templin M, Schenke-Layland K, Tatagiba M, Nahnsen S, Merk DJ,Tabatabai G. Functionally-instructed modifiers of response to ATR inhibition in experimental glioma. J Exp Clin Cancer Res. 2024 Mar 12;43(1):77.doi: 10.1186/s13046-024-02995-z. PMID: 38475864; PMCID: PMC10935927.
Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek HS, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE). Neurooncol Pract. 2024 Jan 20;11(3):336-346. doi: 10.1093/nop/npae002. PMID: 38737615; PMCID: PMC11085831.
Bodensohn R, Fleischmann DF, Maier SH, Anagnostatou V, Garny S, Nitschmann A, Büttner M, Mücke J, Schönecker S, Unger K, Hoffmann E, Paulsen F, Thorwarth D, Holzgreve A, Albert NL, Corradini S, Tabatabai G, Belka C, Niyazi M. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12). Clin Transl Radiat Oncol. 2023 Dec 3;45:100706. doi: 10.1016/j.ctro.2023.100706. PMID: 38116137; PMCID: PMC10726217.
Kurz SC, Stammberger A, Rosahl SK, Abrey LE, Albert NL, Baumgarten LV, Gempt J, Grosu AL, Leidgens V, McLean A, Renovanz M, Schwarzenberger J, Sevenich L, Urbanic Purkart T, Combs SE, Tabatabai G, Hegi M, Nowosielski M. Towards more Diversity in Neuro-oncology Leadership-the DivINe Initiative. Neuro Oncol. 2023 Sep 21:noad157. doi: 10.1093/neuonc/noad157. Epub ahead of print. PMID: 37738478.
Behling F, Paßlack P, Fodi CK, Hielscher T, Schittenhelm J, Nassiri F, Wang JZ, Zadeh G, Tabatabai G, Sahm F. Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2? Neurooncol Adv. 2023 Sep 2;5(1):vdad112. doi: 10.1093/noajnl/vdad112. PMID: 37727848; PMCID: PMC10506376.
Roder C, Stummer W, Coburger J, Scherer M, Haas P, von der Brelie C, Kamp MA, Löhr M, Hamisch CA, Skardelly M, Scholz T, Schipmann S, Rathert J, Brand CM, Pala A, Ernemann U, Stockhammer F, Gerlach R, Kremer P, Goldbrunner R, Ernestus RI, Sabel M, Rohde V, Tabatabai G, Martus P, Bisdas S, Ganslandt O, Unterberg A, Wirtz CR, Tatagiba M. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol. 2023 Jun 19:JCO2201862. doi: 10.1200/JCO.22.01862. Epub ahead of print. PMID: 37335962.
Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med. 2023 Jun;29(6):1298-1301. doi: 10.1038/s41591-023-02354-z. PMID: 37280276.
Wang JZ, Patil V, Liu J, Dogan H, Tabatabai G, Yefet LS, Behling F, Hoffman E, Bunda S, Yakubov R, Kaloti R, Brandner S, Gao A, Cohen-Gadol A, Barnholtz-Sloan J, Skardelly M, Tatagiba M, Raleigh DR, Sahm F, Boutros PC, Aldape K; International Consortium on Meningiomas (ICOM); Nassiri F, Zadeh G. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol. 2023 Jul;146(1):145-162. doi: 10.1007/s00401-023-02571-3. Epub 2023 Apr 24. Acta Neuropathol. 2023 May 12;: PMID: 37093270; PMCID: PMC10261216.
Koch MS, Zdioruk M, Nowicki MO, Hoetker MS, Herbert ZT, Barone F, Tak PP, Chiocca EA, Tabatabai G, Lawler SE. Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models. Front Med (Lausanne). 2023 May 9;10:1140352. doi: 10.3389/fmed.2023.1140352. PMID: 37228396; PMCID: PMC10203593.
Weller M, Le Rhun E, Van den Bent M, Chang SM, Cloughesy TF, Goldbrunner R, Hong YK, Jalali R, Jenkinson MD, Minniti G, Nagane M, Razis E, Roth P, Rudà R, Tabatabai G, Wen PY, Short SC, Preusser M. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. Neuro Oncol. 2023 Jul 6;25(7):1200-1224. doi: 10.1093/neuonc/noad038. PMID: 36843451; PMCID: PMC10326495.
Beer SA, Wirths S, Vogel W, Tabatabai G, Ernemann U, Merle DA, Bethge W, Möhle R, Lengerke C (2023) Patient Reported and Clinical Outcomes after High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma Cancers (Basel) 15(3):669
Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, Niclou SP, Euskirchen P, Haberler C, Hegi ME, Brandner S, Le Rhun E, Rudà R, Sanson M, Tabatabai G, Sahm F, Wen PY, Wesseling P, Preusser M, van den Bent MJ. EANO guideline on rational molecular testing of gliomas, glioneuronal and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 2023 Jan 12:noad008. doi: 10.1093/neuonc/noad008.
Becker, H.; Castaneda-Vega, S.; Patzwaldt, K.; Przystal, J.M.; Walter, B.; Michelotti, F.C.; Canjuga, D.; Tatagiba, M.; Pichler, B.; Beck, S.C.; Holland, E.C.; la Fougère, C.; Tabatabai, G. Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. Brain Sci. 2022, 12, 1426. doi.org/10.3390/brainsci12111426
Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar-Cordova E, Aguilar LK, Guzik BW, Barone F, Tak PP, Schregel K, Hoetker MS, Lederer JA, Chiocca EA, Tabatabai G, Lawler SE. Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. Mol Ther Oncolytics. 2022 Jul 31;26:275-288. doi: 10.1016/j.omto.2022.07.009. PMID: 36032633; PMCID: PMC9391522.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro Oncol. 2022 Apr 14:noac099. doi: 10.1093/neuonc/noac099. Epub ahead of print.
Trautwein C, Zizmare L, Mäurer I, Bender B, Bayer B, Ernemann U, Tatagiba M, Grau SJ, Pichler BJ, Skardelly M, Tabatabai G. Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. JCI Insight. 2022 Feb 8;7(3):e153526. doi: 10.1172/jci.insight.
Walter B, Canjuga D, Yüz SG, Ghosh M, Bozko P, Przystal JM, Govindarajan P, Anderle N, Keller A-L, Tatagiba M, Schenke-Layland K, Rammensee H-G, Stevanovic S, Malek NP, Schmees C, Tabatabai G. Argyrin F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. Adv. Therap. 2021, 2100078.
Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K, Zadeh G. A clinically applicable integrative molecular classification of meningiomas. Nature. 2021 Sep;597(7874):119-125. doi: 10.1038/s41586-021-03850-3. Epub 2021 Aug 25.
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M, Lefranc F, Houdart E, Sallabanda K, Le Rhun E, Nieuwenhuizen D, Tabatabai G, Soffietti R, Weller M. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821-1834. doi: 10.1093/neuonc/noab150.
Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G. Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers (Basel). 2021 May 15;13(10):2400. doi: 10.3390/cancers13102400.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24.
Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, Tabatabai G. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2723-2733. doi: 10.1158/1078-0432.CCR-20-4256. Epub 2021 Feb 23.
Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M; International Consortium on Meningiomas, Schittenhelm J, Tabatabai G. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol. 2021 Aug 2;23(8):1273-1281. doi: 10.1093/neuonc/noaa303.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.
We collaborate closely with national and international partners and alliances, including:
- Deutsches Gliomnetzwerk (German Glioma Network)
- the German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK)
- the European Organisation for Research and Treatment of Cancer (EORTC)
- the European Association of Neuro-Oncology (EANO)
- the International Consortium on Meningioma (ICOM)
Hertie Center of Neurology
Hertie Institute for Clinical Brain Research
Department of Neurology & Interdisciplinary Neuro-Oncology
Otfried-Müller-Straße 27
72076 Tübingen
Phone: +49 (0)7071 29-85018
Fax: +49 (0)7071 29-5957
Phone: +49 (0)7071 29-83269
